Zhang Jing, Li Qiao, Chang Alfred E
Division of Surgical Oncology, University of Michigan Rogel Cancer Center, Room 3410, 1150 East Medical Center Drive, Ann Arbor, MI 48109, USA; Department of the 2nd Thoracic Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 Zhuodaoquan South Road, Hongshan District, Wuhan, Hubei Province 430070, China.
Division of Surgical Oncology, University of Michigan Rogel Cancer Center, 3520B MSRB-1, 1150 West Medical Center Drive, Ann Arbor, MI 48109, USA.
Surg Oncol Clin N Am. 2019 Jul;28(3):431-445. doi: 10.1016/j.soc.2019.02.010. Epub 2019 Apr 10.
Cancer stem cells (CSCs) are crucial for tumor recurrence and distant metastasis. Immunologically targeting CSCs represents a promising strategy to improve efficacy of multimodal cancer therapy. Modulating the innate immune response involving Toll-like receptors, macrophages, natural killer cells, and γδT cells has therapeutic effects on CSCs. Antigens expressed by CSCs provide specific targets for immunotherapy. CSC-primed dendritic cell-based vaccines have induced significant antitumor immunity as an adjuvant therapy in experimental models of established tumors. Targeting the tumor microenvironment CSC niche with cytokines or checkpoint blockade provides additional strategies to eliminate CSCs.
癌症干细胞（CSCs）对肿瘤复发和远处转移至关重要。从免疫学角度靶向癌症干细胞是一种有望提高多模式癌症治疗疗效的策略。调节涉及Toll样受体、巨噬细胞、自然杀伤细胞和γδT细胞的固有免疫反应对癌症干细胞具有治疗作用。癌症干细胞表达的抗原为免疫治疗提供了特定靶点。在已建立肿瘤的实验模型中，以癌症干细胞致敏的树突状细胞为基础的疫苗作为辅助治疗已诱导出显著的抗肿瘤免疫。用细胞因子或检查点阻断靶向肿瘤微环境中的癌症干细胞生态位提供了消除癌症干细胞的额外策略。
